AU2010250957B2 - FVIII-derived peptides - Google Patents

FVIII-derived peptides Download PDF

Info

Publication number
AU2010250957B2
AU2010250957B2 AU2010250957A AU2010250957A AU2010250957B2 AU 2010250957 B2 AU2010250957 B2 AU 2010250957B2 AU 2010250957 A AU2010250957 A AU 2010250957A AU 2010250957 A AU2010250957 A AU 2010250957A AU 2010250957 B2 AU2010250957 B2 AU 2010250957B2
Authority
AU
Australia
Prior art keywords
peptide
fviii
factor viii
peptides
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010250957A
Other languages
English (en)
Other versions
AU2010250957A1 (en
Inventor
David Wraith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apitope International NV
Original Assignee
Apitope International NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010250957(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apitope International NV filed Critical Apitope International NV
Publication of AU2010250957A1 publication Critical patent/AU2010250957A1/en
Assigned to APITOPE INTERNATIONAL NV reassignment APITOPE INTERNATIONAL NV Request for Assignment Assignors: APITOPE TECHNOLOGY (BRISTOL) LIMITED
Application granted granted Critical
Publication of AU2010250957B2 publication Critical patent/AU2010250957B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010250957A 2009-05-18 2010-05-17 FVIII-derived peptides Ceased AU2010250957B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0908515.0A GB0908515D0 (en) 2009-05-18 2009-05-18 Peptide
GB0908515.0 2009-05-18
PCT/GB2010/000997 WO2010133834A2 (en) 2009-05-18 2010-05-17 Peptide

Publications (2)

Publication Number Publication Date
AU2010250957A1 AU2010250957A1 (en) 2011-12-01
AU2010250957B2 true AU2010250957B2 (en) 2015-01-15

Family

ID=40834163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010250957A Ceased AU2010250957B2 (en) 2009-05-18 2010-05-17 FVIII-derived peptides

Country Status (30)

Country Link
US (1) US8703705B2 (enExample)
EP (2) EP2465523B1 (enExample)
JP (1) JP5784009B2 (enExample)
KR (1) KR101673889B1 (enExample)
CN (1) CN102458445B (enExample)
AU (1) AU2010250957B2 (enExample)
BR (1) BRPI1012845A2 (enExample)
CA (1) CA2762020C (enExample)
CL (1) CL2011002893A1 (enExample)
CO (1) CO6460780A2 (enExample)
CY (1) CY1115832T1 (enExample)
DK (1) DK2465523T3 (enExample)
EA (1) EA027229B1 (enExample)
EC (1) ECSP11011540A (enExample)
ES (1) ES2525448T3 (enExample)
GB (1) GB0908515D0 (enExample)
HR (1) HRP20141182T1 (enExample)
IL (1) IL216199A (enExample)
MX (1) MX2011012270A (enExample)
MY (1) MY168207A (enExample)
NZ (2) NZ613713A (enExample)
PL (1) PL2465523T3 (enExample)
PT (1) PT2465523E (enExample)
RS (1) RS53671B1 (enExample)
SG (2) SG190573A1 (enExample)
SI (1) SI2465523T1 (enExample)
SM (1) SMT201400186B (enExample)
UA (1) UA110921C2 (enExample)
WO (1) WO2010133834A2 (enExample)
ZA (1) ZA201108446B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002098454A2 (en) * 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US20050256304A1 (en) * 2002-04-18 2005-11-17 Tim Jones Modified factor VIII
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs
WO2009095646A2 (en) * 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002098454A2 (en) * 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US20050256304A1 (en) * 2002-04-18 2005-11-17 Tim Jones Modified factor VIII
WO2009071886A1 (en) * 2007-12-04 2009-06-11 Apitope Technology (Bristol) Limited Fviii peptides and their use in tolerising haemophiliacs
WO2009095646A2 (en) * 2008-01-28 2009-08-06 Circassia Limited Peptides from factor viii

Also Published As

Publication number Publication date
KR101673889B1 (ko) 2016-11-08
SMT201400186B (it) 2015-01-15
GB0908515D0 (en) 2009-06-24
CA2762020A1 (en) 2010-11-25
CA2762020C (en) 2018-08-28
CN102458445B (zh) 2014-06-11
SI2465523T1 (sl) 2015-02-27
IL216199A0 (en) 2012-01-31
MX2011012270A (es) 2011-12-12
KR20120023023A (ko) 2012-03-12
WO2010133834A3 (en) 2011-02-24
WO2010133834A2 (en) 2010-11-25
US20120121625A1 (en) 2012-05-17
EP2465523B1 (en) 2014-10-01
CL2011002893A1 (es) 2012-08-17
JP5784009B2 (ja) 2015-09-24
HK1173358A1 (en) 2013-05-16
SG176138A1 (en) 2011-12-29
EP2432494A2 (en) 2012-03-28
JP2012527440A (ja) 2012-11-08
HRP20141182T1 (hr) 2015-02-13
DK2465523T3 (en) 2014-12-15
NZ613713A (en) 2014-10-31
PT2465523E (pt) 2014-12-09
SG190573A1 (en) 2013-06-28
US8703705B2 (en) 2014-04-22
NZ596300A (en) 2013-08-30
UA110921C2 (uk) 2016-03-10
EA201171430A1 (ru) 2012-05-30
BRPI1012845A2 (pt) 2016-10-11
CO6460780A2 (es) 2012-06-15
AU2010250957A1 (en) 2011-12-01
EP2465523A1 (en) 2012-06-20
RS53671B1 (sr) 2015-04-30
ECSP11011540A (es) 2012-01-31
ES2525448T3 (es) 2014-12-23
IL216199A (en) 2015-11-30
EA027229B1 (ru) 2017-07-31
PL2465523T3 (pl) 2015-03-31
CY1115832T1 (el) 2017-01-25
ZA201108446B (en) 2013-01-30
CN102458445A (zh) 2012-05-16
MY168207A (en) 2018-10-15

Similar Documents

Publication Publication Date Title
EP2227488B3 (en) Fviii peptides and their use in tolerising haemophiliacs
AU2010250957B2 (en) FVIII-derived peptides
AU2013343024B2 (en) Peptides
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: APITOPE INTERNATIONAL NV

Free format text: FORMER APPLICANT(S): APITOPE TECHNOLOGY (BRISTOL) LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired